Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status
Gastric cancer (GC) and gastroesophageal junction adenocarcinomas (GEJ) are molecularly diverse. TP53 is the most frequently altered gene with approximately 50% of patients harboring mutations. This qualitative study describes the distinct genomic alterations in GCs and GEJs stratified by TP53 mutat...
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2022-04, Vol.27 (4), p.307-313 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 313 |
|---|---|
| container_issue | 4 |
| container_start_page | 307 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 27 |
| creator | Wood, Anthony C Zhang, Yonghong Mo, Qianxing Cen, Ling Fontaine, Jacques Hoffe, Sarah E Frakes, Jessica Dineen, Sean P Pimiento, Jose M Walko, Christine M Mehta, Rutika |
| description | Gastric cancer (GC) and gastroesophageal junction adenocarcinomas (GEJ) are molecularly diverse. TP53 is the most frequently altered gene with approximately 50% of patients harboring mutations. This qualitative study describes the distinct genomic alterations in GCs and GEJs stratified by TP53 mutation status.
Tumor DNA sequencing results of 324 genes from 3741 patients with GC and GEJ were obtained from Foundation Medicine. Association between gene mutation frequency and TP53 mutation status was examined using Fisher's exact test. Functional gene groupings representing molecular pathways suggested to be differentially mutated in TP53 wild-type (TP53WT) and TP53 mutant (TP53MUT) tumors were identified. The association of the frequency of tumors containing a gene mutation in the molecular pathways of interest and TP53 mutation status was assessed using Fisher's exact test with a P-value of |
| doi_str_mv | 10.1093/oncolo/oyac018 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8982441</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A780933865</galeid><sourcerecordid>A780933865</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-69d3cbf60166fc72fcf38933bccbccacdd80a9bfa6215ec087f58c7d065436493</originalsourceid><addsrcrecordid>eNptklFrFDEQx4MotlZffZSAL75sm2yym-yLcNRalVaLd4JvITub3EV2kzPZrdzn6Bdu6p6lQklg_iS_-TOTDEKvKTmmpGEnwUPow0nYaSBUPkGHtOJNwRvy82nWRLJC0Ko5QC9S-kVIlqx8jg5YxSQRlB-im7Nr3U96dMHjYPFqGkLEH74u8NL8nowH59f4u0lTPybsPL7KpPFZ_3HjBp_rNEYHWPtu1sGksN3otdE9_jJ5-Gu76IwPoGP2CoPGyzFmE-tMh9sdXl1VDF9O41zBMscpvUTPrO6TebWPR-jHx7PV6afi4tv559PFRQG8EmNRNx2D1taE1rUFUVqwTDaMtQB5a-g6SXTTWl2XtDJApLCVBNGRuuKs5g07Qu9n3-3UDqaD3FjUvdpGN-i4U0E79f-Ndxu1DtdKNrLknGaDd3uDGPJrpVENLoHpe-1NmJIqay5KSoVgGX07o2vdG-W8DdkR7nC1EDL_JJN1lanjR6i8OjM4CN5Yl88fS4AYUorG3ldPibobEDUPiNoPSE5487Dne_zfRLBbm_C8qA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2647211773</pqid></control><display><type>article</type><title>Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Access via Oxford University Press (Open Access Collection)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Wood, Anthony C ; Zhang, Yonghong ; Mo, Qianxing ; Cen, Ling ; Fontaine, Jacques ; Hoffe, Sarah E ; Frakes, Jessica ; Dineen, Sean P ; Pimiento, Jose M ; Walko, Christine M ; Mehta, Rutika</creator><creatorcontrib>Wood, Anthony C ; Zhang, Yonghong ; Mo, Qianxing ; Cen, Ling ; Fontaine, Jacques ; Hoffe, Sarah E ; Frakes, Jessica ; Dineen, Sean P ; Pimiento, Jose M ; Walko, Christine M ; Mehta, Rutika</creatorcontrib><description>Gastric cancer (GC) and gastroesophageal junction adenocarcinomas (GEJ) are molecularly diverse. TP53 is the most frequently altered gene with approximately 50% of patients harboring mutations. This qualitative study describes the distinct genomic alterations in GCs and GEJs stratified by TP53 mutation status.
Tumor DNA sequencing results of 324 genes from 3741 patients with GC and GEJ were obtained from Foundation Medicine. Association between gene mutation frequency and TP53 mutation status was examined using Fisher's exact test. Functional gene groupings representing molecular pathways suggested to be differentially mutated in TP53 wild-type (TP53WT) and TP53 mutant (TP53MUT) tumors were identified. The association of the frequency of tumors containing a gene mutation in the molecular pathways of interest and TP53 mutation status was assessed using Fisher's exact test with a P-value of <.01 deemed statistically significant for all analyses.
TP53 mutations were noted in 61.6% of 2946 GCs and 81.4% of 795 GEJs (P < .001). Forty-nine genes had statistically different mutation frequencies in TP53WT vs. TP53MUT patients. TP53WT tumors more likely had mutations related to DNA mismatch repair, homologous recombination repair, DNA and histone methylation, Wnt/B-catenin, PI3K/Akt/mTOR, and chromatin remodeling complexes. TP53MUT tumors more likely had mutations related to fibroblast growth factor, epidermal growth factor receptor, other receptor tyrosine kinases, and cyclin and cyclin-dependent kinases.
The mutational profiles of GCs and GEJs varied according to TP53 mutation status. These mutational differences can be used when designing future studies assessing the predictive ability of TP53 mutation status when targeting differentially affected molecular pathways.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1093/oncolo/oyac018</identifier><identifier>PMID: 35380714</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adenocarcinoma - genetics ; Adenocarcinoma - pathology ; Analysis ; Biotechnology ; Cancer ; Care and treatment ; Chromatin ; DNA ; DNA repair ; DNA sequencing ; DNA, Neoplasm ; Epidermal growth factor ; Esophagogastric Junction - pathology ; Fibroblast growth factors ; Gastrointestinal Cancer ; Gene mutations ; Genes ; Genetic aspects ; Humans ; Methylation ; Mutation ; Nucleotide sequencing ; Phosphatidylinositol 3-Kinases - genetics ; Sequence Analysis, DNA ; Stomach cancer ; Tumor proteins ; Tumor Suppressor Protein p53 - genetics ; Tyrosine</subject><ispartof>The oncologist (Dayton, Ohio), 2022-04, Vol.27 (4), p.307-313</ispartof><rights>The Author(s) 2022. Published by Oxford University Press.</rights><rights>COPYRIGHT 2022 Oxford University Press</rights><rights>The Author(s) 2022. Published by Oxford University Press. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-69d3cbf60166fc72fcf38933bccbccacdd80a9bfa6215ec087f58c7d065436493</citedby><cites>FETCH-LOGICAL-c457t-69d3cbf60166fc72fcf38933bccbccacdd80a9bfa6215ec087f58c7d065436493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982441/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982441/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35380714$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wood, Anthony C</creatorcontrib><creatorcontrib>Zhang, Yonghong</creatorcontrib><creatorcontrib>Mo, Qianxing</creatorcontrib><creatorcontrib>Cen, Ling</creatorcontrib><creatorcontrib>Fontaine, Jacques</creatorcontrib><creatorcontrib>Hoffe, Sarah E</creatorcontrib><creatorcontrib>Frakes, Jessica</creatorcontrib><creatorcontrib>Dineen, Sean P</creatorcontrib><creatorcontrib>Pimiento, Jose M</creatorcontrib><creatorcontrib>Walko, Christine M</creatorcontrib><creatorcontrib>Mehta, Rutika</creatorcontrib><title>Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>Gastric cancer (GC) and gastroesophageal junction adenocarcinomas (GEJ) are molecularly diverse. TP53 is the most frequently altered gene with approximately 50% of patients harboring mutations. This qualitative study describes the distinct genomic alterations in GCs and GEJs stratified by TP53 mutation status.
Tumor DNA sequencing results of 324 genes from 3741 patients with GC and GEJ were obtained from Foundation Medicine. Association between gene mutation frequency and TP53 mutation status was examined using Fisher's exact test. Functional gene groupings representing molecular pathways suggested to be differentially mutated in TP53 wild-type (TP53WT) and TP53 mutant (TP53MUT) tumors were identified. The association of the frequency of tumors containing a gene mutation in the molecular pathways of interest and TP53 mutation status was assessed using Fisher's exact test with a P-value of <.01 deemed statistically significant for all analyses.
TP53 mutations were noted in 61.6% of 2946 GCs and 81.4% of 795 GEJs (P < .001). Forty-nine genes had statistically different mutation frequencies in TP53WT vs. TP53MUT patients. TP53WT tumors more likely had mutations related to DNA mismatch repair, homologous recombination repair, DNA and histone methylation, Wnt/B-catenin, PI3K/Akt/mTOR, and chromatin remodeling complexes. TP53MUT tumors more likely had mutations related to fibroblast growth factor, epidermal growth factor receptor, other receptor tyrosine kinases, and cyclin and cyclin-dependent kinases.
The mutational profiles of GCs and GEJs varied according to TP53 mutation status. These mutational differences can be used when designing future studies assessing the predictive ability of TP53 mutation status when targeting differentially affected molecular pathways.</description><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - pathology</subject><subject>Analysis</subject><subject>Biotechnology</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chromatin</subject><subject>DNA</subject><subject>DNA repair</subject><subject>DNA sequencing</subject><subject>DNA, Neoplasm</subject><subject>Epidermal growth factor</subject><subject>Esophagogastric Junction - pathology</subject><subject>Fibroblast growth factors</subject><subject>Gastrointestinal Cancer</subject><subject>Gene mutations</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Humans</subject><subject>Methylation</subject><subject>Mutation</subject><subject>Nucleotide sequencing</subject><subject>Phosphatidylinositol 3-Kinases - genetics</subject><subject>Sequence Analysis, DNA</subject><subject>Stomach cancer</subject><subject>Tumor proteins</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Tyrosine</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptklFrFDEQx4MotlZffZSAL75sm2yym-yLcNRalVaLd4JvITub3EV2kzPZrdzn6Bdu6p6lQklg_iS_-TOTDEKvKTmmpGEnwUPow0nYaSBUPkGHtOJNwRvy82nWRLJC0Ko5QC9S-kVIlqx8jg5YxSQRlB-im7Nr3U96dMHjYPFqGkLEH74u8NL8nowH59f4u0lTPybsPL7KpPFZ_3HjBp_rNEYHWPtu1sGksN3otdE9_jJ5-Gu76IwPoGP2CoPGyzFmE-tMh9sdXl1VDF9O41zBMscpvUTPrO6TebWPR-jHx7PV6afi4tv559PFRQG8EmNRNx2D1taE1rUFUVqwTDaMtQB5a-g6SXTTWl2XtDJApLCVBNGRuuKs5g07Qu9n3-3UDqaD3FjUvdpGN-i4U0E79f-Ndxu1DtdKNrLknGaDd3uDGPJrpVENLoHpe-1NmJIqay5KSoVgGX07o2vdG-W8DdkR7nC1EDL_JJN1lanjR6i8OjM4CN5Yl88fS4AYUorG3ldPibobEDUPiNoPSE5487Dne_zfRLBbm_C8qA</recordid><startdate>20220405</startdate><enddate>20220405</enddate><creator>Wood, Anthony C</creator><creator>Zhang, Yonghong</creator><creator>Mo, Qianxing</creator><creator>Cen, Ling</creator><creator>Fontaine, Jacques</creator><creator>Hoffe, Sarah E</creator><creator>Frakes, Jessica</creator><creator>Dineen, Sean P</creator><creator>Pimiento, Jose M</creator><creator>Walko, Christine M</creator><creator>Mehta, Rutika</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220405</creationdate><title>Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status</title><author>Wood, Anthony C ; Zhang, Yonghong ; Mo, Qianxing ; Cen, Ling ; Fontaine, Jacques ; Hoffe, Sarah E ; Frakes, Jessica ; Dineen, Sean P ; Pimiento, Jose M ; Walko, Christine M ; Mehta, Rutika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-69d3cbf60166fc72fcf38933bccbccacdd80a9bfa6215ec087f58c7d065436493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - pathology</topic><topic>Analysis</topic><topic>Biotechnology</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chromatin</topic><topic>DNA</topic><topic>DNA repair</topic><topic>DNA sequencing</topic><topic>DNA, Neoplasm</topic><topic>Epidermal growth factor</topic><topic>Esophagogastric Junction - pathology</topic><topic>Fibroblast growth factors</topic><topic>Gastrointestinal Cancer</topic><topic>Gene mutations</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Humans</topic><topic>Methylation</topic><topic>Mutation</topic><topic>Nucleotide sequencing</topic><topic>Phosphatidylinositol 3-Kinases - genetics</topic><topic>Sequence Analysis, DNA</topic><topic>Stomach cancer</topic><topic>Tumor proteins</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wood, Anthony C</creatorcontrib><creatorcontrib>Zhang, Yonghong</creatorcontrib><creatorcontrib>Mo, Qianxing</creatorcontrib><creatorcontrib>Cen, Ling</creatorcontrib><creatorcontrib>Fontaine, Jacques</creatorcontrib><creatorcontrib>Hoffe, Sarah E</creatorcontrib><creatorcontrib>Frakes, Jessica</creatorcontrib><creatorcontrib>Dineen, Sean P</creatorcontrib><creatorcontrib>Pimiento, Jose M</creatorcontrib><creatorcontrib>Walko, Christine M</creatorcontrib><creatorcontrib>Mehta, Rutika</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wood, Anthony C</au><au>Zhang, Yonghong</au><au>Mo, Qianxing</au><au>Cen, Ling</au><au>Fontaine, Jacques</au><au>Hoffe, Sarah E</au><au>Frakes, Jessica</au><au>Dineen, Sean P</au><au>Pimiento, Jose M</au><au>Walko, Christine M</au><au>Mehta, Rutika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2022-04-05</date><risdate>2022</risdate><volume>27</volume><issue>4</issue><spage>307</spage><epage>313</epage><pages>307-313</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>Gastric cancer (GC) and gastroesophageal junction adenocarcinomas (GEJ) are molecularly diverse. TP53 is the most frequently altered gene with approximately 50% of patients harboring mutations. This qualitative study describes the distinct genomic alterations in GCs and GEJs stratified by TP53 mutation status.
Tumor DNA sequencing results of 324 genes from 3741 patients with GC and GEJ were obtained from Foundation Medicine. Association between gene mutation frequency and TP53 mutation status was examined using Fisher's exact test. Functional gene groupings representing molecular pathways suggested to be differentially mutated in TP53 wild-type (TP53WT) and TP53 mutant (TP53MUT) tumors were identified. The association of the frequency of tumors containing a gene mutation in the molecular pathways of interest and TP53 mutation status was assessed using Fisher's exact test with a P-value of <.01 deemed statistically significant for all analyses.
TP53 mutations were noted in 61.6% of 2946 GCs and 81.4% of 795 GEJs (P < .001). Forty-nine genes had statistically different mutation frequencies in TP53WT vs. TP53MUT patients. TP53WT tumors more likely had mutations related to DNA mismatch repair, homologous recombination repair, DNA and histone methylation, Wnt/B-catenin, PI3K/Akt/mTOR, and chromatin remodeling complexes. TP53MUT tumors more likely had mutations related to fibroblast growth factor, epidermal growth factor receptor, other receptor tyrosine kinases, and cyclin and cyclin-dependent kinases.
The mutational profiles of GCs and GEJs varied according to TP53 mutation status. These mutational differences can be used when designing future studies assessing the predictive ability of TP53 mutation status when targeting differentially affected molecular pathways.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>35380714</pmid><doi>10.1093/oncolo/oyac018</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2022-04, Vol.27 (4), p.307-313 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8982441 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Access via Oxford University Press (Open Access Collection); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adenocarcinoma - genetics Adenocarcinoma - pathology Analysis Biotechnology Cancer Care and treatment Chromatin DNA DNA repair DNA sequencing DNA, Neoplasm Epidermal growth factor Esophagogastric Junction - pathology Fibroblast growth factors Gastrointestinal Cancer Gene mutations Genes Genetic aspects Humans Methylation Mutation Nucleotide sequencing Phosphatidylinositol 3-Kinases - genetics Sequence Analysis, DNA Stomach cancer Tumor proteins Tumor Suppressor Protein p53 - genetics Tyrosine |
| title | Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T00%3A06%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20Tumor%20DNA%20Sequencing%20Results%20in%20Patients%20with%20Gastric%20and%20Gastroesophageal%20Junction%20Adenocarcinoma%20Stratified%20by%20TP53%20Mutation%20Status&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Wood,%20Anthony%20C&rft.date=2022-04-05&rft.volume=27&rft.issue=4&rft.spage=307&rft.epage=313&rft.pages=307-313&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1093/oncolo/oyac018&rft_dat=%3Cgale_pubme%3EA780933865%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2647211773&rft_id=info:pmid/35380714&rft_galeid=A780933865&rfr_iscdi=true |